Prognosis value of central venous oxygen saturation in acute decompensated heart failure

Autor: Romain Gallet, Nicolas Lellouche, Pascal Gueret, Pascal Lim, Laurens Mitchell-Heggs, Belaid Bouhemad, Alexandre Bensaid, Jean-Luc Dubois-Randé
Rok vydání: 2011
Předmět:
Inotrope
Male
medicine.medical_specialty
Cardiotonic Agents
Acute decompensated heart failure
medicine.medical_treatment
Insuffisance cardiaque aiguë
Severity of Illness Index
Ventricular Function
Left
Transplantation cardiaque
Oxygen Consumption
Internal medicine
medicine
Humans
cardiovascular diseases
Prospective Studies
Prospective cohort study
Cardiogenic shock
Heart transplantation
Heart Failure
Ejection fraction
business.industry
Acute heart failure
Stroke Volume
General Medicine
Stroke volume
Saturation veineuse centrale en oxygène
Middle Aged
medicine.disease
Prognosis
Surgery
Oxygen
Central venous oxygen saturation
Acute Disease
Cardiology
cardiovascular system
Disease Progression
Heart transplant
Female
business
Cardiology and Cardiovascular Medicine
Mace
Choc cardiogénique
Follow-Up Studies
Zdroj: Archives of cardiovascular diseases. 105(1)
ISSN: 1875-2128
Popis: SummaryBackgroundCentral venous oxygen saturation (ScvO2) provides an estimation of body oxygen consumption/delivery ratio. Its use has been suggested for monitoring treatment of patients admitted for acute decompensated heart failure (ADHF) but the optimal target value has never been clearly reported.AimsWe aimed to address the prognostic value of ScvO2 in ADHF requiring inotrope support.MethodsScvO2 was prospectively assessed in 60 patients with ADHF requiring inotrope support (mean age 62±16 years; 45 men; left ventricular ejection fraction 25±7%) and was compared with major adverse cardiac events (MACE), defined as heart transplantation, cardiac assistance and death.ResultsMACE occurred in 22 (35%) patients (14 deaths; eight referred for heart transplantation or cardiac assistance). Admission ScvO2 (mean 57±13%) did not differ between patients with and without MACE. At 24hours ScvO2 (mean 62±7%) increased only in patients without MACE (65±6% vs. 58±7%; p60% at 24hours.ConclusionIn patients admitted for ADHF requiring inotrope support, ScvO2≤60% despite optimal treatment is a marker of poor outcome and might be an indicator for considering more aggressive therapy.
Databáze: OpenAIRE
Externí odkaz: